XML 18 R12.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Non-financial Assets and Liabilities | 3 Months Ended
--- | ---
Sep. 30, 2022
Disclosure Of Non Financial Assets And Liabilities [Abstract] |
Non-financial Assets and Liabilities | 6. Non-financial assets and liabilities
a. | Intangible assets
(in U.S. dollars, in thousands) |  | Goodwill |  |  | Acquired licenses to patents |  |  | In-process research and development acquired |  |  | Current marketed products |  |  | Total |
Year Ended June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Opening net book amount |  |  | 134,453 |  |  |  | 2,072 |  |  |  | 427,779 |  |  |  | 16,242 |  |  |  | 580,546 |
Additions/(reversals) |  |  | — |  |  |  | (450 | ) |  |  | — |  |  |  | — |  |  |  | (450 | )
Exchange differences |  |  | — |  |  |  | 74 |  |  |  | — |  |  |  | 1 |  |  |  | 75 |
Amortization charge |  |  | — |  |  |  | (64 | ) |  |  | — |  |  |  | (1,455 | ) |  |  | (1,519 | )
Closing net book amount |  |  | 134,453 |  |  |  | 1,632 |  |  |  | 427,779 |  |  |  | 14,788 |  |  |  | 578,652 |
As of June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost |  |  | 134,453 |  |  |  | 2,987 |  |  |  | 489,698 |  |  |  | 24,000 |  |  |  | 651,138 |
Accumulated amortization |  |  | — |  |  |  | (1,355 | ) |  |  | — |  |  |  | (9,212 | ) |  |  | (10,567 | )
Accumulated impairment |  |  | — |  |  |  | — |  |  |  | (61,919 | ) |  |  | — |  |  |  | (61,919 | )
Net book amount |  |  | 134,453 |  |  |  | 1,632 |  |  |  | 427,779 |  |  |  | 14,788 |  |  |  | 578,652 |
Three Months Ended September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Opening net book amount |  |  | 134,453 |  |  |  | 1,632 |  |  |  | 427,779 |  |  |  | 14,788 |  |  |  | 578,652 |
Additions/(reversals) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Exchange differences |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Amortization charge |  |  | — |  |  |  | (13 | ) |  |  | — |  |  |  | (364 | ) |  |  | (377 | )
Closing net book amount |  |  | 134,453 |  |  |  | 1,619 |  |  |  | 427,779 |  |  |  | 14,424 |  |  |  | 578,275 |
As of September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost |  |  | 134,453 |  |  |  | 2,961 |  |  |  | 489,698 |  |  |  | 24,000 |  |  |  | 651,112 |
Accumulated amortization |  |  | — |  |  |  | (1,342 | ) |  |  | — |  |  |  | (9,576 | ) |  |  | (10,918 | )
Accumulated impairment |  |  | — |  |  |  | — |  |  |  | (61,919 | ) |  |  | — |  |  |  | (61,919 | )
Net book amount |  |  | 134,453 |  |  |  | 1,619 |  |  |  | 427,779 |  |  |  | 14,424 |  |  |  | 578,275 |
(i) Carrying value of in-process research and development acquired by product
|  |  |  | As of September 30, |  |  | As of June 30, |
(in U.S. dollars, in thousands) |  |  |  | 2022 |  |  | 2022 |
Cardiovascular products(1) |  |  |  |  | 254,351 |  |  |  | 254,351 |
Intravenous products for metabolic diseases and inflammatory/immunologic conditions(2) |  |  |  |  | 70,730 |  |  |  | 70,730 |
MSC products(3) |  |  |  |  | 102,698 |  |  |  | 102,698 |
|  |  |  |  | 427,779 |  |  |  | 427,779 |
(1) | Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction
(2) | Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy
(3) | Includes remestemcel-L for the treatment of children with SR-aGVHD and remestemcel-L for the treatment of Crohn’s disease
For all products included within the above balances, the underlying currency of each item recorded is US$. During the quarter ended September 30, 2022, no impairment indicators for the in-process research and development and goodwill were identified.
b. | Provisions
|  | As of |  |  | As of |
|  | September 30, 2022 |  |  | June 30, 2022 |
(in U.S. dollars, in thousands) |  | Current |  |  | Non-current |  |  | Total |  |  | Current |  |  | Non-current |  |  | Total |
Contingent consideration |  |  | 11,685 |  |  |  | 9,816 |  |  |  | 21,501 |  |  |  | 10,823 |  |  |  | 12,461 |  |  |  | 23,284 |
Employee benefits |  |  | 4,020 |  |  |  | 37 |  |  |  | 4,057 |  |  |  | 3,333 |  |  |  | 62 |  |  |  | 3,395 |
Provision for license agreements |  |  | 3,750 |  |  |  | — |  |  |  | 3,750 |  |  |  | 3,750 |  |  |  | — |  |  |  | 3,750 |
|  |  | 19,455 |  |  |  | 9,853 |  |  |  | 29,308 |  |  |  | 17,906 |  |  |  | 12,523 |  |  |  | 30,429 |
(i) Information about individual provisions and significant estimates Contingent consideration The contingent consideration provision relates to the Group’s liability for certain milestones and royalty achievements pertaining to the acquired MSC assets from Osiris. Further disclosures can be found in Note 5(e)(iii). Employee benefits The provision for employee benefits relates to the Group’s liability for annual leave, short term incentives and long service leave. Employee benefits include accrued annual leave. As at September 30, 2022 and June 30, 2022, the entire amount of the annual leave accrual was $1.0 million and $1.0 million respectively, and is presented as current, since the Group does not have an unconditional right to defer settlement for any of these obligations. (ii) Movements The contingent consideration provision relates to the Group’s liability for certain milestones and royalty achievements. Refer to Note 5(e)(iii) for movements in contingent consideration for the period ended September 30, 2022 and June 30, 2022.
c. | Deferred tax balances
(i) Deferred tax balances
|  | As of September 30, |  |  | As of June 30, |
(in U.S. dollars, in thousands) |  | 2022 |  |  | 2022 |
Deferred tax assets |  |  |  |  |  |  |  |
The balance comprises temporary differences attributable to: |  |  |  |  |  |  |  |
Tax losses |  |  | 79,813 |  |  |  | 80,411 |
Other temporary differences |  |  | 8,368 |  |  |  | 7,831 |
Total deferred tax assets |  |  | 88,181 |  |  |  | 88,242 |
Deferred tax liabilities |  |  |  |  |  |  |  |
The balance comprises temporary differences attributable to: |  |  |  |  |  |  |  |
Intangible assets |  |  | 88,181 |  |  |  | 88,242 |
Total deferred tax liabilities |  |  | 88,181 |  |  |  | 88,242 |
Net deferred tax liabilities |  |  | — |  |  |  | — |
(ii) Movements
(in U.S. dollars, in thousands) |  | Tax losses(1) (DTA) |  |  | Other temporary differences(1) (DTA) |  |  | Intangible assets (DTL) |  |  | Total (DTL) |
As of June 30, 2021 |  |  | (71,916 | ) |  |  | (8,248 | ) |  |  | 80,164 |  |  |  | — |
Charged/(credited) to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
- profit or loss |  |  | (8,742 | ) |  |  | 425 |  |  |  | 8,078 |  |  |  | (239 | )
- directly to equity |  |  | 247 |  |  |  | (8 | ) |  |  | — |  |  |  | 239 |
As of June 30, 2022 |  |  | (80,411 | ) |  |  | (7,831 | ) |  |  | 88,242 |  |  |  | — |
Charged/(credited) to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
- profit or loss |  |  | 543 |  |  |  | (537 | ) |  |  | (61 | ) |  |  | (55 | )
- directly to equity |  |  | 55 |  |  |  | — |  |  |  | — |  |  |  | 55 |
As of September 30, 2022 |  |  | (79,813 | ) |  |  | (8,368 | ) |  |  | 88,181 |  |  |  | — |
(1) | Deferred tax assets are netted against deferred tax liabilities

X
- Definition Disclosure of non financial assets and liabilities, + References No definition available. + Details
Name: | meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract
Namespace Prefix: | meso_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of non financial assets and non financial liabilities. + References No definition available. + Details
Name: | meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatory
Namespace Prefix: | meso_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration